» Articles » PMID: 15478066

Targeting Virological Core Groups: a New Paradigm for Controlling Herpes Simplex Virus Type 2 Epidemics

Overview
Journal J Infect Dis
Date 2004 Oct 13
PMID 15478066
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Classic modeling of sexually transmitted diseases has focused on modeling behavioral heterogeneity and designing epidemic control strategies targeted at behavioral core groups.

Methods: We analyzed a new mathematical model of herpes simplex virus type 2 (HSV-2) epidemics that includes virological core groups (i.e., groups of individuals with high rates of viral reactivation) and suggest a new paradigm for epidemic control. We used our model, in conjunction with virological data, to determine the potential role of virological core groups in contributing to transmission and the effect that daily antiviral therapy (DAT) could have on reducing transmission if virological core groups were targeted.

Results: We estimated that a virological core group (11% of infected individuals) can cause a disproportionately large percentage (44%) of new infections and that a median of only 6.4 person-years of DAT would be necessary to prevent 1 HSV-2 infection. We determined that relatively few individuals would need to receive DAT to substantially reduce the incidence of HSV-2 infection.

Conclusion: Identifying and targeting individuals in the virological core group could be an effective and practical public health strategy for reducing transmission. Treating individuals who are high-frequency viral shedders should be evaluated as a strategy for reducing HSV-2 transmission.

Citing Articles

Epidemiological impact of a genital herpes type 2 vaccine for young females.

Lou Y, Qesmi R, Wang Q, Steben M, Wu J, Heffernan J PLoS One. 2012; 7(10):e46027.

PMID: 23071536 PMC: 3469571. DOI: 10.1371/journal.pone.0046027.


Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.

Alsallaq R, Schiffer J, Longini Jr I, Wald A, Corey L, Abu-Raddad L Sex Transm Dis. 2010; 37(5):290-7.

PMID: 20351622 PMC: 2860045. DOI: 10.1097/OLQ.0b013e3181d3d023.


Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling.

Magaret A, Johnston C, Wald A Sex Transm Infect. 2009; 85(4):270-5.

PMID: 19211593 PMC: 2730769. DOI: 10.1136/sti.2008.034751.


Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.

Crespi C, Cumberland W, Wald A, Corey L, Blower S Sex Transm Infect. 2007; 83(5):359-64.

PMID: 17475687 PMC: 2659025. DOI: 10.1136/sti.2006.022020.


Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.

Herbst-Kralovetz M, Pyles R J Virol. 2006; 80(20):9988-97.

PMID: 17005677 PMC: 1617314. DOI: 10.1128/JVI.01099-06.